| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
Vasopressin is a peptide hormone that is also named as antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin. It is a hormone that regulates the body′s retention of water.
| ln Vitro |
In Chinese hamster ovary cells expressing rat or human V1b receptors, AVP (0.01 nM-1 μM) causes an elevation in Ca2+[2].
|
|---|---|
| ln Vivo |
Vasopressin (0.03-0.3μg/kg; ip) enhances corticotropin secretion after body water loss and amplifies corticotropin release triggered by exogenous corticoliberin[2]. ? Potently increasing nearby laying, vasopressin (0.001-0.1μg/kg; ip) causes rats to lie passively next to one other when they first meet[3].
|
| Animal Protocol |
Adult male Long-Evans rats (250-300 g) were housed in groups under a reverse 12:12 h light-dark cycle and handled daily for 7 days before testing. All drugs were administered via intraperitoneal (IP) injection at a volume of 1 ml/kg. AVP was purchased from AusPep Ltd and dissolved in physiological saline (0.9%) to produce doses of 0.001, 0.0025, 0.005, 0.01, and 0.1 mg/kg. [2]
**Social Interaction Test:** Rats were tested in black rectangular arenas lined with bedding, under dim red light. On the day before testing, rats were individually habituated to the arena for 60 min. On test days, rats were weight-paired (±10 g) with an unfamiliar conspecific given the same drug treatment. Rats were placed in the test arena for 30 min, starting 10 min after AVP injection. Behaviors scored by a blind observer included adjacent lying, general investigation, anogenital sniffing, and rearing. A counterbalanced design was used for the dose-response study, with each rat receiving all doses of AVP and saline, with two washout days between treatments and a new partner each time. [2] **Antagonist Study Protocol (Experiment 5):** In a between-groups design, pairs of rats (N=4 per condition) were administered either (1) vehicle + vehicle, (2) SR49059 (1 mg/kg) + vehicle, (3) vehicle + AVP (0.01 mg/kg), or (4) SR49059 (1 mg/kg) + AVP (0.01 mg/kg). Injections were given 15 min apart, and rats were tested for social interaction for 30 min, starting 10 min after the second injection. SR49059 was dissolved in a vehicle of 15% DMSO, 2% Tween-80, and 83% saline. [2] **Drug Combination Protocol (Experiment 9):** In a between-groups design, pairs of rats (N=4 per condition) were randomly assigned to (1) saline + saline, (2) saline + AVP (0.0025 mg/kg), (3) saline + MDMA (2.5 mg/kg), or (4) AVP (0.0025 mg/kg) + MDMA (2.5 mg/kg). Injections were administered 10 min apart, and the 30-min test began 10 min after the second injection. [2] |
| References |
|
| Exact Mass |
1049.45
|
|---|---|
| CAS # |
11000-17-2
|
| PubChem CID |
11979316
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.509
|
| Hydrogen Bond Donor Count |
27
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
38
|
| Heavy Atom Count |
148
|
| Complexity |
4030
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C(C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(CC)C)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(N)CSSC2)=O)CCCC1C(NC(C(=O)N(C(=O)N)C)CCC/N=C(/N)\N)=O
|
| InChi Key |
KBZOIRJILGZLEJ-LGYYRGKSSA-N
|
| InChi Code |
InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
| Chemical Name |
(S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide
|
| Synonyms |
argipressinH-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide Bridge Cys1-Cys6)arginine vasopressin (AVP) Vasopressin antidiuretic hormone (ADH)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~92.23 mM)
H2O : ~50 mg/mL (~46.12 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (23.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00628550 | COMPLETED | Drug: Vasopressin Drug: Epinephrine |
Cardiac Arrest Cardiopulmonary Arrest |
University of Texas Southwestern Medical Center | 2008-04 | Phase 1 |
| NCT06426407 | NOT YET RECRUITING | Drug: Vasopressin | Shock, Septic | The Cleveland Clinic | 2024-06 | |
| NCT02377492 | WITHDRAWN | Drug: Vasopressins | Myoma | University Hospitals Cleveland Medical Center | 2015-03 | Not Applicable |
| NCT06422975 | RECRUITING | Drug: Vasopressin | Vasopressin Causing Adverse Effects in Therapeutic Use Vasopressin Deficiency Shock Vasopressor Adverse Reaction |
Hospital Universitario 12 de Octubre | 2024-07-09 | |
| NCT01393704 | COMPLETEDWITH RESULTS | Drug: Vasopressin | Blood Loss, Surgical | Brigham and Women's Hospital | 2011-07 | Phase 4 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
